Lovero Grazia, Borghi Elisa, Balbino Stella, Cirasola Daniela, De Giglio Osvalda, Perdoni Federica, Caggiano Giuseppina, Morace Giulia, Montagna Maria Teresa
Department of Biomedical Science and Human Oncology, Hygiene Section, Università degli Studi of Bari "Aldo Moro", Bari, Italy.
Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
PLoS One. 2016 Feb 26;11(2):e0150218. doi: 10.1371/journal.pone.0150218. eCollection 2016.
The Candida parapsilosis group encompasses three species: C. parapsilosis, C. orthopsilosis, and C. metapsilosis. Here, we describe the incidence and echinocandin susceptibility profile of bloodstream isolates of these three species collected from patients admitted to an Italian university hospital from 2007 to 2014. Molecular identification of cryptic species of the C. parapsilosis complex was performed using polymerase chain reaction amplification of the gene encoding secondary alcohol dehydrogenase, followed by digestion with the restriction enzyme BanI. Minimum inhibitory concentrations were determined using the broth microdilution method according to European Committee for Antimicrobial Susceptibility Testing (EUCAST EDef 7.2) and Clinical Laboratory Standards Institute (CLSI M27-A3) guidelines, and the results were compared with those obtained using the E-test and Sensititre methods. Of the 163 C. parapsilosis complex isolates, 136 (83.4%) were identified as C. parapsilosis, and 27 (16.6%) as C. orthopsilosis. The species-specific incidences were 2.9/10,000 admissions for C. parapsilosis and 0.6/10,000 admissions for C. orthopsilosis. No resistance to echinocandins was detected with any of the methods. The percent essential agreement (EA) between the EUCAST and E-test/Sensititre methods for anidulafungin, caspofungin, and micafungin susceptibility was, respectively, as follows: C. parapsilosis, 95.6/97.8, 98.5/88.2, and 93.4/96.3; C. orthopsilosis, 92.6/92.6, 96.3/77.8, and 63.0/66.7. The EA between the CLSI and E-test/Sensititre methods was, respectively, as follows: C. parapsilosis, 99.3/100, 98.5/89.0, and 96.3/98.5; C. orthopsilosis, 96.3/92.6, 100/81.5, and 92.6/88.9. Only minor discrepancies, ranging from 16.9% (C. parapsilosis) to 11.1% (C. orthopsilosis), were observed between the CLSI and E-test/Sensititre methods. In conclusion, this epidemiologic study shows a typical C. parapsilosis complex species distribution, no echinocandin resistance, and it reinforces the relevance of using commercially available microbiological methods to assess antifungal susceptibility. These data improve our knowledge of the national distribution of species of the psilosis group, as there are very few studies of these species in Italy.
近平滑念珠菌、正平滑念珠菌和副平滑念珠菌。在此,我们描述了2007年至2014年期间从一家意大利大学医院收治的患者中分离出的这三种菌种的血流感染发生率及棘白菌素敏感性情况。使用编码仲醇脱氢酶的基因进行聚合酶链反应扩增,随后用限制性内切酶BanI消化,对近平滑念珠菌复合体的隐匿菌种进行分子鉴定。根据欧洲抗菌药物敏感性试验委员会(EUCAST EDef 7.2)和美国临床和实验室标准协会(CLSI M27 - A3)的指南,采用肉汤微量稀释法测定最低抑菌浓度,并将结果与使用E-test法和Sensititre法获得的结果进行比较。在163株近平滑念珠菌复合体分离株中,136株(83.4%)被鉴定为近平滑念珠菌,27株(16.6%)为正平滑念珠菌。近平滑念珠菌的菌种特异性发病率为每10000例入院患者中有2.9例,正平滑念珠菌为每10000例入院患者中有0.6例。使用任何一种方法均未检测到对棘白菌素的耐药性。EUCAST法与E-test法/Sensititre法在阿尼芬净、卡泊芬净和米卡芬净敏感性方面的基本一致率(EA)分别如下:近平滑念珠菌,95.6/97.8、98.5/88.2和93.4/96.3;正平滑念珠菌,92.6/92.6、96.3/77.8和63.0/66.7。CLSI法与E-test法/Sensititre法的EA分别如下:近平滑念珠菌,99.3/100、98.5/89.0和96.3/98.5;正平滑念珠菌,96.3/92.6、100/81.5和92.6/88.9。CLSI法与E-test法/Sensititre法之间仅观察到微小差异,范围从16.9%(近平滑念珠菌)到11.1%(正平滑念珠菌)。总之,这项流行病学研究显示了典型的近平滑念珠菌复合体菌种分布,未发现棘白菌素耐药情况,并强化了使用商业微生物学方法评估抗真菌药物敏感性的相关性。这些数据增进了我们对意大利国内平滑念珠菌组菌种分布的了解,因为在意大利对这些菌种的研究非常少。